Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1492-1503

  Fang, Yong ^a,c   Cao, Zipeng ^c   Hou, Qi ^b   Ma, Chen ^b   Yao, Chunsuo ^b   Li, Jingxia ^c   Wu, Xue Ru ^d   Huang, Chuanshu ^c,d  

^a ZHEJIANG UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c Nelson Institute of Environmental Medicine   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; ISORHAPONTIGENIN; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOINFORMATICS; BLADDER CANCER; CANCER CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CHINESE HERB; CHROMATIN IMMUNOPRECIPITATION; DOWN REGULATION; GENETIC TRANSCRIPTION; GNETUM; GNETUM CLEISTOSTACHYUM; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; PROMOTER REGIONS, GENETIC; SP1 TRANSCRIPTION FACTOR; STILBENES; TRANSCRIPTION, GENETIC; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882253724     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0922     Document Type: Article

References (59)

1. Holick CN, Giovannucci EL, Stampfer MJ, Michaud DS. A prospective study of fish, marine fatty acids, and bladder cancer risk among men and women (United States). Cancer Causes Control 2006;17: 1163-73.
2. Gerullis H, Ecke TH, Janusch B, Arndt C, Heidari M, Oniani J, et al. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance. Anticancer Drugs 2011;22:940-3.
3. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374:239-49.
4. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006;37:1568-76.
5. Ikoma T, Ozawa S, Suzuki K, Kondo T, Maehata Y, Lee MC, et al. Calcium-calmodulin signaling induced by epithelial cell differentiation upregulates BRAK/CXCL14 expression via the binding of SP1 to the BRAK promoter region. Biochem Biophys Res Commun 2012;420: 217-22.
6. Yuan L, Gu X, Shao J, Wang M, Wang M, Zhu Q, et al. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol 2010;29: 611-7.
7. Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU, Diehl JA. Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene 2008;27:1231-42.
8. Ciznadija D, Liu Y, Pyonteck SM, Holland EC, Koff A. Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma. Cancer Res 2011;71:6174-83.
9. Tashiro E, Maruki H, Minato Y, Doki Y, Weinstein IB, Imoto M. Overexpression of cyclin D1 contributes to malignancy by up-regulation of fibroblast growth factor receptor 1 via the pRB/E2F pathway. Cancer Res 2003;63:424-31.
10. Yamada M, Hayashi K, Ikeda S, Tsutsui K, Ito T, Iinuma M, et al. Inhibitory activity of plant stilbene oligomers against DNA topoisomerase II. Biol Pharm Bull 2006;29:1504-7.
11. Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Ochiya T. Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity. Sci Rep 2012;2:314.
12. Huang KS, Wang YH, Li RL, Lin M. Stilbene dimers from the lianas of Gnetum hainanense. Phytochemistry 2000;54:875-81.
13. Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, et al. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res 2005;65: 9287-93.
14. Jenkins TD, Mueller A, Odze R, Shahsafaei A, Zukerberg LR, Kent R, et al. Cyclin D1 overexpression combined with N-nitrosomethylbenzylamine increases dysplasia and cellular proliferation in murine esophageal squamous epithelium. Oncogene 1999;18:59-66.
15. Marampon F, Casimiro MC, Fu M PM, Popov VM, Lindsay J, Zani BM, et al. Nerve Growth factor regulation of cyclin D1 in PC12 cells through a p21RAS extracellular signal-regulated kinase pathway requires cooperative interactions between Sp1 and nuclear factor-kappaB. Mol Biol Cell 2008;19:2566-78.
16. Slansky JE, Li Y, Kaelin WG, Farnham PJ. A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol 1993;13:1610-8.
17. Huang HY, Shariat SF, Sun TT, Lepor H, Shapiro E, Hsieh JT, et al. Persistent uroplakin expression in advanced urothelial carcinomas: Implications in urothelial tumor progression and clinical outcome.Hum Pathol 2007;38:1703-13.
18. Huang C, Ma WY, Ryan CA, Dong Z. Proteinase inhibitors I and II from potatoes specifically block UV-induced activator protein-1 activation through a pathway that is independent of extracellular signal-regulated kinases, c-Jun N-terminal kinases, and P38 kinase. Proc Natl Acad Sci U S A 1997;94:11957-62.
19. Huang C, Ma WY, Young MR, Colburn N, Z. D. Shortage of mitogenactivated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci U S A 1998;95:156-61.
20. Huang C, Ma WY, Dong Z. Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P ?cells. Mol Cell Biol 1996;16:6427-35.
21. Fang Y, Yu Y, Hou Q, Zhen X, Zhang M, Zhang D, et al. The Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by downregulating overexpression of antiapoptotic protein XIAP. J Biol Chem 2012;287:35234-43.
22. Zhang D, Li J, Costa M, Gao J, Huang C. JNK1 mediates degradation HIF-1alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70. Cancer Res 2010;70:813-23.
23. Zhang D, Li J, Zhang M, Gao G, Zuo Z, Yu Y, et al. The Requirement of c-Jun N-terminal kinase2 in Regulation of hypoxia inducing factor-1&[alpha] mRNA Stability. J Biol Chem 2012;287:34361-71.
24. Li J, Chen H, Tang MS, Shi X, Amin S, Desai D, et al. PI-3K and Akt are mediators of AP-1 induction by 5-MCDE in mouse epidermal Cl41 cells. J Cell Biol 2004;165:77-86.
25. Song L, Li J, Zhang D, Liu ZG, Ye J, Zhan Q, et al. IKKbeta programs to turn on the GADD45alpha-MKK4-JNK apoptotic cascade specifically via p50 NF-kappaB in arsenite response. J Cell Biol 2006;175:607-17.
26. Song L, Gao M, Dong W, Hu M, Li J, Shi X, et al. p85alpha mediates p53 K370 acetylation by p300 and regulates its promoter-specific transactivity in the cellular UVB response. Oncogene 2011;30:1360-71.
27. Huang KS, Zhou S, Lin M, Wang YH. An isorhapontigenin tetramer and a novel stilbene dimer from Gnetum hainanense. Planta Med 2002; 68:916-20.
28. Liu Y, Liu G. Isorhapontigenin and resveratrol suppress oxLDLinduced proliferation and activation of ERK1/2 mitogen-activated protein kinases of bovine aortic smooth muscle cells. Biochem Pharmacol 2004;67:777-85.
29. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM, et al. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med 2005;38:243-57.
30. China Pharmaceutical University, editor. Chinese medicine Cihai (Volume 2). China Medical Science and Technology Press 1997:2365-66.
31. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
32. Lee CC, Yamamoto S, Wanibuchi H, Wada S, Sugimura K, Kishimoto T, et al. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation. Cancer Res 1997;57:4765-76.
33. Keenan SM, Lents NH, Baldassare JJ. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression. J Biol Chem 2004;279:5387-96.
34. Singh RP, Agarwal C, Agarwal R. Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: Modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 2003;24:555-63.
35. Kim JK, Diehl JA. Nuclear cyclin D1: An oncogenic driver in human cancer. J Cell Physiol 2009;220:292-6.
36. Rajabi H, Ahmad R, Jin C, Kosugi M, Alam M, Joshi MD, et al. MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem 2012;287:10703-13.
37. Satinder K, Chander SR, Pushpinder K, Indu G, Veena J. Cyclin D1 (G870A) polymorphism and risk of cervix cancer: A case control study in north Indian population. Mol Cell Biochem 2008;315:151-7.
38. Ogino S, Nosho K, Irahara N, Kure S, Shima K, Baba Y, et al. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res 2009;15:4431-8.
39. Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN. High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology 2011;58:781-9.
40. Burnworth B, Popp S, Stark HJ, Steinkraus V, Brocker EB, Hartschuh W, et al. Gain of 11q/cyclin D1 overexpression is an essential early step in skin cancer development and causes abnormal tissue organization and differentiation. Oncogene 2006;25:4399-412.
41. Kristt D, Turner I, Koren R, Ramadan E, Gal R. Overexpression of cyclin D1 mRNA in colorectal carcinomas and relationship to clinicopathological features: An in situ hybridization analysis. Pathol Oncol Res 2000;6:65-70.
42. Lehn S, Tobin NP, Berglund P, Nilsson K, Sims AH, Jirstrom K, et al. Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol 2010;177:2886-97.
43. Meng H, Tian L, Zhou J, Li Z, Jiao X, Li WW, et al. PACSIN 2 represses cellular migration through direct association with cyclin D1 but not its alternate splice form cyclin D1b. Cell Cycle 2011;10:73-81.
44. Li Z, Wang C, Jiao X, Lu Y, Fu M, Quong AA, et al. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 2006;26:4240-56.
45. Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006;108:1744-50.
46. Xiao Y, Wang J, Lu J, Liu Y, Wang Y, Gao Y, et al. Down-regulation of cyclin D1 by small interfering RNA inhibits cell growth and induces apoptosis of laryngeal squamous cell carcinoma. Am J Otolaryngol 2011;32:541-6.
47. Yang K, Guo Y, Stacey WC, Harwalkar J, Fretthold J, Hitomi M, et al. Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels. BMC Cell Biol 2006;30:33.
48. Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, et al. microRNA-365, downregulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis 2012;33:220-5.
49. Musgrove EA. Cyclins: Roles in mitogenic signaling and oncogenic transformation. Growth Factors 2006;24:13-9.
50. Klein EA, Yang C, Kazanietz MG, Assoian RK. NFkappaB-independent signaling to the cyclin D1 gene by Rac. Cell Cycle 2007;6:1115-21.
51. Bartusel T, Schubert S, Klempnauer KH. Regulation of the cyclin D1 and cyclin A1 promoters by B-Myb is mediated by Sp1 binding sites. Gene 2005;351:171-80.
52. Liu Y, Hock JM, Sullivan C, Fang G, Cox AJ, Davis KT, et al. Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arseniteinduced cell proliferation. J Cell Biochem 2010;111:1546-55.
53. Ouyang W, Li J, Ma Q, Huang C. Essential roles of PI-3K/Akt/IKKbeta/ NFkappaB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis 2006;27:864-73.
54. Ouyang W, Luo W, Zhang D, Jian J, Ma Q, Li J, et al. PI-3K/Akt pathway-dependent cyclin D1 expression is responsible for arsenite-induced human keratinocyte transformation. Environ Health Perspect 2008;116:1-6.
55. D'Amico M, Hulit J, Amanatullah DF, Zafonte BT, Albanese C, Bouzahzah B, et al. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 2000;275: 32649-57.
56. Motokura T, Arnold A. PRAD1/cyclin D1 proto-oncogene: Genomic organization, 5' DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosomes Cancer 1993;7: 89-95.
57. Herber B, Truss M, Beato M, Muller R. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 1994;9:2105-7.
58. Vartanian R, Masri J, Martin J, Cloninger C, Holmes B, Artinian N, et al. AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: Role of AIP4/Itch-mediated JUNB degradation. Mol Cancer Res 2011;9:115-30.
59. Seznec J, Silkenstedt B, Naumann U. Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. J Neurooncol 2011;101: 365-77.